Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 06 May 2017
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 23 Jan 2016 Trial design presented at the 2016 Gastrointestinal Cancers Symposium
- 25 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 01 Jan 2015 Planned End Date changed from 1 Jun 2018 to 1 Jul 2018 as reported by ClinicalTrials.gov record.